Introduction {#s0001}
============

Tuberculosis (TB) remains a major public health problem globally, accounting 10 millioncases (range: 9.0--11.1 million); surprisingly two-thirds represents the developing country.[@cit0001] Moreover, in 2017, TB remained one of the top 10 causes of death and the leading cause from a single infectious agent, with an estimated 1.3 million deaths (range: 1.2--1.4 million), worldwide.[@cit0001] Emergence of drug-resistant TB continues to be a significant public health crisis, and has further worsened the situation and become a significant obstacle to effective TB control.[@cit0002] According to global tuberculosis reports, worldwide in 2017, 558,000 people (range: 483,000--639,000) developed TB that was resistant to rifampicin (RR-TB), the most effective ﬁrst line drug, and of these, 82% had multidrug-resistant TB (MDR-TB). Globally, 3.5% of new TB cases and 18% of previously treated cases had MDR/RR-TB[@cit0001]

TB remains one of the leading public health problems in Nepal. According to the 2016/17 national tuberculosis programme, a total of 31,764 cases of TB were identified. The estimated annual incidence rate of all forms of TB is 111/100,000, whereas the incidence rate of new and relapse is 108/100,000 population.[@cit0003]

One of the greatest risk factors for drug-resistant TB is problems in treatment and diagnosis, especially in developing countries. If TB is identified and treated early, drug resistance can be avoided. The rapid detection of *Mycobacterium tuberculosis* (MTB) is crucial for early diagnosis and management of disease to minimize the high risk of disease transmission from person to person and emergence of MDR-TB. Xpert MTB/Rif assay, endorsed by WHO, is able to assess simultaneously detection of *M. tuberculosis* and rifampicin resistance mutation in the *rpoB* gene within two hours.[@cit0004],[@cit0005] The Xpert assay is highly rapid, sensitive and specific in diagnosis of both pulmonary and extra pulmonary tuberculosis.[@cit0006]--[@cit0008] Additionally, it was shown to be cost-effective for TB diagnosis compared to microscopy in resource limited countries.[@cit0009]

Moreover, the prevalence of MTB and RR/MTB and its contributing factors described in literature vary largely across countries, which may also differ from Nepal. However, to date, the prevalence of MTB and RR-MTB has not been addressed extensively in the Nepalese setting. Therefore, the present study was aimed at assessing the rate of RR-MTB using the Xpert MTB/Rif assay, and further to identify the influencing factors associated with it.

Methods {#s0002}
=======

Study Design {#s0002-s2001}
------------

This was a retrospective cross-sectional study where data were evaluated retrospectively from the patients over a one year period from February 2018 to January 2019.

Study Setting {#s0002-s2002}
-------------

This study was conducted at National Tuberculosis Center (NTC), Bhaktpur Nepal. This is a referral governmental hospital where the referral patients from different health services across the country visit the hospital for diagnosis and treatment of the disease.

Outcome Variables {#s0002-s2003}
-----------------

The core variable used for the study was MTB and RR-MTB. The covariates included in this study were: age, sex, ethnic group, geographic diversity, TB treatment history.

Study Population and Selection {#s0002-s2004}
------------------------------

Presumptive TB patients who visited NTCTuberculosis Center for the diagnosis and treatment of the disease, who met the inclusion criteria were enrolled in the study. To be eligible, all age groups with signs and symptoms suggestive of TB underwent the GeneXpert Rif/MTB assay test and smear test. Patients with insufficient demographic and clinical information were excluded from the study. A total 197 records of study participants who had no records of smear test were excluded from 1187 subjects, resulting in 990.

Data Collection {#s0002-s2005}
---------------

A structured questionnaire and checklist was used for the data collection. Patient's demographic including age, sex, ethnicity, TB treatment history, geographic diversity and results of smear test for bacteriological presentation or not, rifampicin resistance using the GeneXpert/MTB assay was assessed retrospectively from the patient's medical chart as well as from laboratory chart.

Laboratory investigation {#s0002-s2006}
------------------------

From the respiratory specimen collected, acid fast bacilli microscopy and Xpert MTB/RIF assay was performed. If the presence of MTB was detected, GeneXpert was also used to look for evidence of rifampicin resistance.

From the sample, MTB bacilli was purified and concentrated by the Xpert MTB/RIF. Genomic material was isolated from the captured bacteria by sonication and the genomic DNA subsequently amplified by PCR. Furthermore, all the clinically relevant rifampicin resistance, inducing mutations in the *rpoB* gene in the MTB genome in a real-time format using fluorescent probes called molecular beacons were identified. Internal quality controls (sample processing control and probe check control) were used during the assay.

GeneXpert MTB/RIF Assay {#s0002-s2007}
-----------------------

GeneXpert analysis was performed in accordance to the protocol provided by its manufacturer (Cepheid, Sunnyvale, CA, USA), module GX-IV-4. Sputum specimens were used directly for the test. Briefly, the sample-reagent (SR) (Cepheid) was added at a 2:1 ratio to the sputum sample and incubated for 15 min at room temperature. The treated sample was shaken gently during incubation and then transferred into the cartridge.

Data Processing and Analysis {#s0002-s2008}
----------------------------

The data collected from TB registration book were entered into an excel spreadsheet and then exported to SPSS version 20 (IBM Corporation, Armonk, NY, USA) for analysis. Continuous data were presented as mean ±SD. Descriptive data were presented as frequency and percentage. Rifampicin resistance was the outcome variable. The association between the outcome variable test status and independent variables were computed using Chi-square test and where applicable Fisher's exact test. Crude OR of associated factors (age, sex, ethnicity, geographic diversity) of the outcome variables was determined. Confidence interval was set at 95% and *P* value less than 0.05% considered to be statistically significant for all tests.

Ethical Aspects {#s0002-s2009}
---------------

Study protocol was approved by the NTC for commencement of the study. To ensure the confidentiality of the participants\' information, data were anonymously used; and any other confidential information was highly secured. Since we used secondary data, informed consent was not sought from the study participants.

Results {#s0003}
=======

The estimated prevalence of MTB among presumptive TB patients was 13.8%, with lower limit 11.88% and upper limit 16.16% ([Table 1](#t0001){ref-type="table"}) Table 1Prevalence of *Mycobacterium tuberculosis* (MTB)Total Sample Size\
(n)MTB+ (n=137)95%CIPrevalence (%)LL (%)UL (%)99013.811.8816.16

Demographics and associations of MTB with sociodemographic parameters are presented in [Table 2](#t0002){ref-type="table"}. This retrospective cross-sectional study was conducted among 990 presumptive tuberculosis cases. Median ages of the patients were 39±19.09 years ([@cit0001]--93), and two-thirds of the patients were male 653 (66.0%).Table 2Demographics and Association of Sociodemographic Characteristics with *Mycobacterium tuberculosis* (MTB), and Bivariate Analysis of Risk Factors for Positive MTBParametersMTB+ Cases\
n (%)\
n=137MTB-- Cases\
n (%)\
n=853Total\
n=990*P* valueOR (95%CI)*P* valueAge (median) (continuous)39.88±18.7341.52±19.1539±19.09(1--93)0.351.005 (0.99--1.04)0.35Age (category)0.91 \<154 (2.92)27 (3.17)311.17 (0.38--3.5)0.78 15--3966 (48.18)400 (46.89)4661.051 (0.65--1.67)0.83 40--5937 (27.01)253 (29.66)2901.18 (0.17--1.93)0.52 ≥6030 (21.90)173 (20.28)2031Gender0.77 Male92 (67.15)561 (65.77)6530.94 (0.64--1.34)0.75 Female45 (32.85)292 (34.23)3371Ethnicity0.53 Brahmin/Chhetri27 (19.71)211 (25.91)2381.56 (0.71--3.34)0.26 Janjati94 (68.61)547 (64.13)6411.16 (0.57--2.43)0.67 Madhesi6(4.38)45(5.28)511.50 (0.50--4.45)0.46 Dalit10 (7.30)50 (5.86)601Geographical diversity0.51 Himalayan18 (13.14)108 (12.66)1260.62 (0.30--1.30)0.21 Mountain (hilly)104 (75.91)602 (70.57)7060.609 (0.34--1.07)0.087 Plain (Terai)15 (10.95)143 (16.76)1581Treatment history0.000 Retreatment after failure47 (34.31)48 (5.62)9510.33 (6.47--16.38)\<0.001 Recurrence10 (7.29)9 (1.06)190.91 (0.34--2.46)0.86 New80 (58.39)796 (93.32)8761Treatment history with anti-TB drugs0.000 Previously treated57(41.60)57 (6.68)11410.44 (6.77--16.12)\<0.001 Previously not treated80 (58.39)796 (93.32)8761

Mean ages of MTB+ patients had lower positive finding compared to those of MTB-- patients, without there being a significant difference (*P*\>0.05). The highest positive finding for MTB 30 (14.78%) was observed in the age group above 60 years, whereas four (12.9%) MTB prevalent were reported in pediatric patients. Proportion of positive MTB was slightly higher in male 92 (14.08%) than female 45 (13.35%) patients. With respect to ethnicity, Dalit caste repreported to have the highest 10 (16.66%) rate of MTB. Patients residing in hilly regions appeared to have higher 104 (14.37%) positive findings of MTB. Categorical analysis for significance of association of MTB towards age, sex, ethnicity and geographical diversity was null (*P*\>0.05). Proportion of MTB+ was significantly higher in previously treated patients 57 (50.00) compared to treatment-naïve patients 80 (9.13) (*P*\<0.001), and the odds of developing MTB were significantly higher in previously treated patients: OR: 10.44 (95%CI: 6.77--16.12, *P*\<0.001)

As shown in [Table 3](#t0003){ref-type="table"}, the estimated prevalence of RR-MTB in TB-confirmed patients was 10.2%, with 4.97% lower level and 15.1% upper level. Table 3Prevalence of Rifampicin-resistant *Mycobacterium tuberculosis* (RR-MTB) Among Presumptive PatientsTotal Sample Size\
(n)RR-MTB (n=14)95%CIPrevalence (%)LL (%)UL (%)13710.24.9715.1

Association between RR-MTB and patient's sociodemographic characteristics are illustrated in [Table 4](#t0004){ref-type="table"}. Rate of rifampicin-resistant TB in the pediatric population was predominantly higher 1 (25%), compared to other ages groups, 15--39 years and 40--60 years, with 7 (10.60%) and 4 (10.81%) respectively. Female subjects had nearly twice 7 (15.55%) as many RR-TB as male 7 (7.60%) patients. With respect to ethnical group, proportion of RR-MTB was higher in Madhesi, Janjati and Dalit with 1 (16.66%), 12 (12.76%) and 1 (10.00%), respectively. Patients belonging to the Terai region had higher rate RR-MTB 3 (20.0%), compared to Himalayan 2 (11.11%) and hilly region 9 (8.65%). Proportion of RR-MTB was predominantly higher in previously treated patients 8 (13.79%), compared to treatment-naive patients 6 (7.50%). No significant association between RR-MTB and age, sex, ethnicity, geographical diversity and previous history of treatment failure was observed (*P*\>0.05).Table 4Association Between Sociodemographic Characteristics and Rifampicin Resistant MTB Among TB Confirmed Patients, and Bivariate Analysis of Risk Factors for RR-MTB**ParametersMTB+/RR+**\
**n (%)**\
**n=14MTB+/RR-**\
**n(%)**\
**n=123Total**\
**n=137*P*** value\
**(χ^2^)OR (95%CI)*P*** valueAge (continuous)37.36±21.1340.00±18.500.610.99 (0.96--1.023)0.61Age (category)0.70 \<151 (7.14)3 (2.44)41 15--397 (50.00)59 (47.97)664.66 (0.32--68.0)0.26 40--594 (28.57)33 (26.83)371.66 (0.32--8.5)0.54 ≥602 (14.29)28 (22.76)301.69 (0.28--9.8)0.55Gender0.22 Male7 (50.00)85 (69.11)922.23 (0.73--6.85)0.15 Female7 (50.00)38 (30.89)451Ethnicity0.26 Bahun/Chhetri0 (0.00)27 (21.95)27---- Janjati12 (85.71)82 (66.67)941.31 (0.15--11.3)0.80 Madhesi1 (7.14)5 (4.7)61.8 (0.091--35.42)0.69 Dalit1 (7.14)9 (7.32)101Geographical diversity0.39 Himalayan2 (14.29)16 (13.01)180.48 (0.072--3.48)0.50 Mountain (hilly)9 (64.29)95 (77.24)1040.37 (0.90--1.59)0.37 Plain (Terai)3 (21.43)12 (9.76)151Treatment history0.45 Retreatment after failure7 (50.00)41 (33.33)482.077 (0.65--6.78)0.21 Recurrence1 (7.14)9 (7.32)101.35 (0.14--12.53)0.79 New6 (42.86)73 (59.35)791Previous treatment history0.23 Previously treated8 (57.14)50 (40.65)581.94 (0.63--5.93)0.24 Previously not treated6 (42.86)73 (59.35)801

Discussion {#s0004}
==========

Rifampicin remains the most effective drug to treat TB, and the advent of resistance to it has had enormous impact on the TB-control program. Several epidemiological studies have attempted to unveil the impact and management of multidrug resistant-TB, however, little is known about the rifampicin-resistant TB, especially in Nepal. In this study several important findings were noted.

Studies around the world have reported a diverse magnitude of *M. tuberculosis* infection. In the present study the prevalence of *M. tuberculos*is was found to be 13.8% which is lower than the estimates of earlier studies, ranges from 15.4--25%, in different study settings.[@cit0010]--[@cit0013] However, this estimate is lower compared to the previous reports in Mali (10%)[@cit0014] and Mexico (7.5%).[@cit0015] This variation could be explained by the difference in geographical variation, methods of diagnosis, study setting, or TB control practice.

The prevalence of *M. tuberculosis* among pediatric TB patients (12.9%) in the present study is comparable to the reports from South Africa (13%)[@cit0016] and Uganda (14%).[@cit0017] However, it is lower than a study conducted in Southwest Ethiopia (31.7%).[@cit0018] Owing to different cut-off points for age groups applied in previous literature, it is difficult to make it comparable with ours regarding the association between MTB and age groups. Based on our study results, there was no significant association between age groups and MTB (*P*\>0.05). The results of our study refute the association of an earlier study,[@cit0012] where the age group stratified by \<10 years 10--16 years, 17--23 years, 24--30 years, 31 to 37 years, 38--44 years, 45--51, 52--58 and \>58 was significantly associated with MTB. Likewise, in a study conducted by Mulu et al, in Debre Markos referral hospital, Ethiopia,[@cit0013] age group ≤10, 11--17, 18--30, 31--40, 41--50,51-60, and 61--92 was significantly associated with the patients with and without evidence of MTB (*P*\<0.05). These variations across the studies could be attributed to the difference in sample size and difference in cut-off points for age groups.

Moreover, in agreement with the earlier studies,[@cit0013],[@cit0019],[@cit0020] our study demonstrated a high rate of MTB, 66 (14.16) in age group 15--39 years. This might be due to more exposure in outer environment, high workload and wide range of mobility of this age group people to acquire the TB bacilli.

In this study, the detection rate of *M. tuberculosis* among male subjects (14.08%) was slightly higher than female subjects (13.35%). This is comparable with a study from Eastern Uttar Pradesh, India,[@cit0021] a population-based prevalence survey of TB in the Tigray region of Ethiopia[@cit0022] and a report from WHO.[@cit0023] Although, the proportion of male MTB subjects were higher than female MTB, the difference was not significant (*P*\>0.05), which also confirms the earlier study.[@cit0012] However, in a study conducted by Mulu et al, in Debre Markos refferal hospital, Ethiopia,[@cit0013] the proportion of MTB male subjects were significantly higher than MTB female subjects (*P*\<0.05). This difference in sex incidence could be related to the social and health-seeking behavior difference, environmental factors, and tendency of higher exposure of males to the outer environment; smoking and alcoholism are different factors that pose a risk of acquiring the TB bacilli.[@cit0023]

There was a lack of association between MTB and age, sex, ethnicity, and geographic distribution and history of anti-TB drug (*P*\>0.05). However, history of previous treatment failure was significantly correlated with MTB (*P*\<0.001).

A study conducted in northwest Ethiopia revealed no significant association of MTB with sex and history of previous treatment failure. However, age, defined as stratified by \<10, 10--16, 17--23, 24--30, 31--37, 38--44, 45--51, 52--58, and \>58 years was significantly associated with MTB.[@cit0012]

Regarding treatment history, comparable results were reported by Gautam et al,[@cit0021] in Eastern Uttar Pradesh India, in Debre Markos referral hospital, Ethiopia,[@cit0013] and in Zimbabwe,[@cit0024] where prevalence of MTB were significantly predominated in patients with previously treated cases compared to treatment-naive patients (*P*\<0.05).

The existence of RR-MTB is a serious global health burden. RR-MTB is substantially high in low-income middle countries which may be attributed to its demographic and socioeconomic profile like poverty, lack of knowledge, poor practice, overcrowding, malnutrition, and care during illness and lack of social security. The overall prevalence of RR-MTB among TB confirmed cases was 10.2%. The prevalence of RR-MTB in this study is in line with previous studies reported in Ethiopia (10.3%),[@cit0013] Nigeria (13.9%),[@cit0025] and North India (10.5%).[@cit0026] However, this figure is higher than that demonstrated in various parts of the world, with a prevalence of 2.5%,[@cit0027] 3.4%,[@cit0010] 5.7%,[@cit0028] 7.5%[@cit0029] and is lower indicated in some region of Ethiopia 15.8--33.3%.[@cit0012],[@cit0027],[@cit0030]

The variation of RR-TB across the nation could be related to differences in patient selection, sample size (small sampling could generate high resistance rate), disparities in awareness of studied populations about drug resistance, access to health-care facilities, treatment and poor patient adherence.

With respect to the relationship between RR-MTB and age group, earlier study, conducted in referral hospital in Lagos, Nigeria, showed that being aged ≥45 years was independently associated with RR-TB.[@cit0031] In the previous study conducted in India, age strata (01--20, 20--40, 40--60, 60--80) was significantly associated with RR-MTB.[@cit0021] Report from Ethiopia indicated similar finding,[@cit0010] where age 1--15, 16--30, 31--45, 46--60, \>60 was significantly correlated with RR-TB. In comparison, Our study revealed no significant association between RR-MTB and age, which is also supported by one earlier study.[@cit0032] The insignificant association between RR-MTB and age in this study in our study could be due to the difference in sample size and difference in cut-off points for age groups.

Regarding the association between sex and MTB, there are no conclusive reports. For instance; studies from Ethiopia,[@cit0027],[@cit0032] Georgia,[@cit0033] and Russia[@cit0034] have demonstrated that RR-MTB is associated with sex. However, in consonant with our study, study conducted by Jaleta et al in Northwest Ethiopia and Mulu et al in Debre Markos referral hospital Ethiopia revealed no significant association between RR-TB and sex.[@cit0012],[@cit0013] In the present study, proportion of RR-MTB in female was insignificantly higher than male counterpart (15.55% vs 7.60%). The high rate of RR-MTB among female subjects in our study could be explained by the socioeconomic factors (probably due to lack of control of financial resources at household levels) and delay in seeking health care in females. However, further study in a large population in the Nepalese setting should justify this possible association.

Studies across the countries have shown a substantial variation in the prevalence of RR-MTB in patients with previous anti-TB drug history and new cases. In the present study, the proportion of RR-MTB in previously treated cases (13.79%), which is higher than that reported in an earlier study (2.4%),[@cit0035] and is lower compared to different study settings, 16.5%,[@cit0012] (17.1%)[@cit0013] 27.4%.[@cit0032] The proportion of RR-MTB in new cases in this study (7.59%) is in accordance with previous studies (6.7%),[@cit0013] (7.6%),[@cit0013] yet lower than that reported in earlier studies (13.0%),[@cit0012] 27.6%.[@cit0036]

Earlier studies have indicated a significant association between RR-MTB and history of anti-TB drugs, and have shown that RR-MTB is significantly higher in previously treated cases compared to new cases.[@cit0013],[@cit0032] In our study, although there was a lack of association between these variables, prevalence of RR-MTB in previously treated cases (13.79%) were higher compared to treatment-naïve patients (5.75%). The high prevalence of RR-MTB in previously treated cases patients suggest that previously treated patients were more likely to harbor drug-resistant strains, and is suggestive of weakness in TB prevention and control measures, as it is conveyed by resistance to rifampicin in new cases as well. This indicates that transmission of RR-MTB has a considerable role in this epidemic, and high frequency of treatment abandonment in earlier days may contribute toward high levels of resistance. Moreover, poor quality of anti-TB drugs used, inappropriate intake of medications and poor management of drug-sensitive TB could contribute to the higher rate of RR-MTB. A population-based survey which analyzed data from 11 countries demonstrated that the chance of developing resistant TB increased with the longer length of treatment as a result of treatment failure.[@cit0037]

In the present study, occurrence of MTB and RR-MTB were not significantly different among ethnic groups (Brahmin/Chhetri, Janjati, Madhesi, and Dalit) as well among the patients residing in different geographically diverse regions of the country (Himalayan, hilly, and Terai). Thus, the findings indicate that the ethnical groups and geographical diversity of the patients are not the contributing factors for the occurrence of MTB and RR-MTB. However, further supporting studies in a large representative population is needed to draw the conclusion.

Limitations {#s0005}
===========

We acknowledge that this study was accomplished with some limitations. First, a lower rate RR-MTB in this study might have affected the results of logistic regression analysis for significance of association.

Second, although the study was conducted in a large sample size, this study was limited to the TB referral hospital in Bhaktpur, Nepal. Therefore, a larger nationwide study using the Xpert assay will provide a better estimate of RR-MTB in Nepal. Despite this limitation, this study became the first to demonstrate the rifampicin resistance in MTB using Xpert in Nepal which can be a further asset for planning of TB management and tackling further increase in the resistance.

Conclusion {#s0006}
==========

Our study unveiled a high rate MTB in Nepalese presumptive TB patients. Occurrence of MTB was significantly associated with the history of anti-TB drugs, and previous treatment with anti-TB drug appeared to be independent predictors for MTB. Our study also demonstrated a high rate of RR-MTB among MTB confirmed patients, and high rate was observed in both previously treated patients and treatment-naïve patients. Thus, MTB and RR-MTB in our Nepalese setting remained an unresolved issue that needs to be addressed soon, and there is a need for improved monitoring of treatment to limit the spread of drug-resistant TB.
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